This meeting took place in 2018
Here are the related meetings in 2019:
Tuberculosis: Mechanisms, Pathogenesis and Treatment (A3)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Tuberculosis: Translating Scientific Findings for Clinical and Public Health Impact (X7)
Organizer(s) Graeme Meintjes, Eric J. Rubin and Sabine Ehrt
April 15—19, 2018
Fairmont Chateau Whistler • Whistler, British Columbia Canada
Discounted Abstract Deadline: Dec 13, 2017
Abstract Deadline: Jan 11, 2018
Scholarship Deadline: Dec 13, 2017
Discounted Registration Deadline: Feb 15, 2018
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
Summary of Meeting:
It is estimated that one-third of the world’s population is infected with tuberculosis, and each year 10 million people develop disease, with 1.5 million tuberculosis-related deaths. Global control efforts using currently available diagnostic, treatment and preventive tools are predicted to achieve only gradual reductions in global tuberculosis incidence. Critical factors impeding tuberculosis control are the ability of Mycobacterium tuberculosis to evade host-killing mechanisms and enter into a phenotypic state of persistence with risk of later reactivation, HIV co-infection which drives progression to disease, the emergence and transmission of drug-resistant strains, our limited understanding of the immune responses necessary to kill or effectively contain Mycobacterium tuberculosis and how to elicit these with a novel vaccine. To accelerate progress in TB control, deeper fundamental insights into the pathogen and pathogen-host interactions are required, and these then need to be translated into more effective tools at a public health level. Under the theme of translation, this conference brings together laboratory, clinical and epidemiological tuberculosis researchers to engage the key scientific questions in tuberculosis science including persistence, metabolic adaptation, immune evasion, prediction and early diagnosis of progression to disease, drug resistance, discovery of novel drug targets, and determinants of morbidity and mortality. This will allow for cross-talk between disciplines and triangulation of research findings from epidemiological and clinical studies and laboratory and animal models. The meeting explores what fundamental insights are needed to advance TB control and how fundamental insights can be translated for clinical and public health impact. For the first time, the meeting is held jointly with the Keystone Symposia’s “HIV and Co-Infections: Pathogenesis, Inflammation and Persistence” conference, which will facilitate discussion around HIV and tuberculosis co-infection and explore synergies in the respective fields.
View Meeting Program
It is estimated that one-third of the world’s population is infected with tuberculosis, and each year 10 million people develop disease, with 1.5 million tuberculosis-related deaths. Global control efforts using currently available diagnostic, treatment and preventive tools are predicted to achieve only gradual reductions in global tuberculosis incidence. Critical factors impeding tuberculosis control are the ability of Mycobacterium tuberculosis to evade host-killing mechanisms and enter into a phenotypic state of persistence with risk of later reactivation, HIV co-infection which drives progression to disease, the emergence and transmission of drug-resistant strains, our limited understanding of the immune responses necessary to kill or effectively contain Mycobacterium tuberculosis and how to elicit these with a novel vaccine. To accelerate progress in TB control, deeper fundamental insights into the pathogen and pathogen-host interactions are required, and these then need to be translated into more effective tools at a public health level. Under the theme of translation, this conference brings together laboratory, clinical and epidemiological tuberculosis researchers to engage the key scientific questions in tuberculosis science including persistence, metabolic adaptation, immune evasion, prediction and early diagnosis of progression to disease, drug resistance, discovery of novel drug targets, and determinants of morbidity and mortality. This will allow for cross-talk between disciplines and triangulation of research findings from epidemiological and clinical studies and laboratory and animal models. The meeting explores what fundamental insights are needed to advance TB control and how fundamental insights can be translated for clinical and public health impact. For the first time, the meeting is held jointly with the Keystone Symposia’s “HIV and Co-Infections: Pathogenesis, Inflammation and Persistence” conference, which will facilitate discussion around HIV and tuberculosis co-infection and explore synergies in the respective fields.
View Meeting Program
Scholarships/Awards
Keystone Symposia Future of Science Fund Scholarship Recipients
Christopher R. CoveyUniversity of Colorado, USA
Karin Dijkman
Biomedical Primate Research Centre, Netherlands
Ved Prakash Dwivedi
International Center for Genetic Engineering and Biotechnology, India
Valerie A.C.M. Koeken
Radboud University Medical Center, Netherlands
National Institute of Allergy and Infectious Diseases (NIAID) Scholarship Recipients
Piyali S. BasuUniversity of Surrey, UK
Yuxiang Chen
Tsinghua University, China
Sarah Bwabye Namugenyi
University of Minnesota, USA
Mark Ragheb
University of Washington, USA
Keystone Symposia Global Health Travel Award Recipients, funded by the Bill & Melinda Gates Foundation
Funded by Keystone Symposia Global Health Travel Award Recipients, funded by the Bill & Melinda Gates Foundation
Patience Antigha Ubong AkpanUniversity of Calabar, Nigeria
Prince Asare
Noguchi Memorial Institute for Medical Research, Ghana
Foluke Adenike Ayeni
University of Lagos, Nigeria
Richard Baguma
Institute of Infectious Disease & Molecular Medicine, South Africa
Saikou Y. Bah
University of Ghana, Ghana
Chia Julius Ebua
, South Africa
Martins Ochubiojo Emeje
National Institute for Pharmaceutical Research and Development, Nigeria
Paulin Essone Ndong
Centre de Recherches Médicales de Lambaréné, Gabon
Lutete Peguy Khonde
University of Cape Town, South Africa
Marisa Klopper
Stellenbosch University, South Africa
Savita Lochab
National Institute of Immunology, India
Alyne Fávero Galvão Meirelles
University of São Paulo, Brazil
Solomon Ali Mohammed
Jimma University, Ethiopia
Johana Monteserin
Instituto Nacional de Enfermedades Infecciosas, Argentina
Nneka I. Onyejepu
Nigerian Institute of Medical Research, Nigeria
Caroline Mosonngwa Pule
University of Stellenbosch, South Africa
Kriti Sikri
All India Institute of Medical Sciences, India
Samuel Sunday Taiwo
Ladoke Akintola University of Technology, Nigeria
Sakshi Talwar
Translation Health Science and Technology Institute, India
Maria Belen Vecchione
INBIRS,
